Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV

Autor:	Yves, Lévy, Rodolphe, Thiébaut, Marie-Lise, Gougeon, Jean-Michel, Molina, Laurence, Weiss, Pierre-Marie, Girard, Alain, Venet, Philippe, Morlat, Béatrice, Poirier, Anne-Sophie, Lascaux, Céline, Boucherie, Daniel, Sereni, Christine, Rouzioux, Jean-Paul, Viard, Cliff, Lane, Jean-François, Delfraissy, Irini, Sereti, Geneviève, Chêne
Rok vydání:	2012
Předmět:	Adult CD4-Positive T-Lymphocytes Male Interleukin 2 medicine.medical_specialty Time Factors Anti-HIV Agents CD8 Antigens medicine.medical_treatment Immunology HIV Infections Gastroenterology Internal medicine Humans Immunology and Allergy Medicine IL-2 receptor Sida Chemotherapy biology business.industry Interleukin-2 Receptor alpha Subunit Interleukin T lymphocyte Middle Aged Viral Load biology.organism_classification ADP-ribosyl Cyclase 1 CD4 Lymphocyte Count Treatment Outcome Infectious Diseases Case-Control Studies Lentivirus Interleukin-2 RNA Viral Drug Therapy Combination Female Viral disease business Follow-Up Studies medicine.drug
Zdroj:	AIDS. 26:711-720
ISSN:	0269-9370
Popis:	BACKGROUND Interleukin (IL)-2 therapy impacts T-cell homeostasis. Whether IL-2 expanded CD4(+) T cells may persist following viral rebound has not been fully investigated. METHODS Patients with CD4(+) T cells 500/μl or more and HIV RNA less than 50 copies/ml were randomized to continue antiretroviral therapy (ART) either alone (n = 67) or combined with three IL-2 cycles (n = 81; 6 million units) twice daily for 5 days at weeks 0, 8, and 16 before stopping ART (week 24). Patients were followed up to 168 weeks. RESULTS At week 24, median CD4(+) T-cell counts were 1198 and 703 cells/μl in the IL-2 and control groups, respectively (P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::590444813af93f4709ba6f56c6899bb0 https://doi.org/10.1097/qad.0b013e3283519214 Zobrazit plný text záznamu